FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause
View all alerts
Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

nitroglycerin (GONITRO, MINITRAN, NITRO-BID, NITRO-DUR, NITROLINGUAL PUMPSPRAY, NITROMIST, NITROSTAT, TRANSDERM-NITRO)


DRUG AND DIETARY SUPPLEMENT PROFILES

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a secondary subject of discussion.

sildenafil [erectile dysfunction] (VIAGRA); tadalafil (ADCIRCA, ALYQ, CIALIS, TADLIQ); vardenafil (LEVITRA, STAXYN)

WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Watch out for Interactions Between Drugs for Erectile Dysfunction and Other Medications
January 2009
The article lists 56 drugs that can interact with the three drugs for erectile dysfunction (ED): sildenafil (VIAGRA), tadalafil (CIALIS) and vardenafil (LEVITRA). Eight of the drugs are either nitrates such as nitroglycerin or a certain group of high blood pressure drugs.In combination with ED drugs, these drugs can cause a dangerous fall in blood pressure that could lead to a heart attack or stroke. Thirty-two other drugs can inhibit the enzyme that helps the body to eliminate the ED drugs, resulting in abnormally high blood levels of the drugs and a potentially harmful "overdose" even though you are actually taking the recommended amount. The other 16 drugs speed up the metabolism of the ED drugs, thereby lowering the blood levels and reducing the effectiveness of the ED drugs.
A Review of Ranolazine (RANEXA) For Chronic Chest Pain
March 2007
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.
Written Drug Information Sheets Distributed by Pharmacists Fail to Meet Minimum Quality Standards
August 2002
The Food and Drug Administration (FDA) announced on June 18, 2002, the results of a national study to determine the extent of distribution and the quality of unregulated written drug information, known as “patient information leaflets” (PILs), produced by commercial information vendors to be disseminated by pharmacists to drug consumers when prescriptions are filled. The study’s results were appalling.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion.

Comments before FDA Drug Safety Advisory Committee on Patient Drug Information (HRG Publication #1629)
The failure of the private sector to meet the quality goals established in The Action Plan and thus the failure to achieve the distribution goal of 75 percent of patients getting scientifically accurate information leaves only one option under Public Law 104-180: the Secretary [Department of Health and Human Services] shall seek public comment on other initiatives that may be carried out to meet such goals.

Show primary search results for nitroglycerin (GONITRO, MINITRAN, NITRO-BID, NITRO-DUR, NITROLINGUAL PUMPSPRAY, NITROMIST, NITROSTAT, TRANSDERM-NITRO)

Disclaimer

The information on this website is not intended to substitute for professional medical advice, diagnosis, or treatment. Consult your doctor before changing or discontinuing any medication.